🏢 Peptide Industry Competitive Landscape Analysis (2024-2026)¶
Report ID: MKI-CL-2026-001 | Release Date: July 2026
Coverage: Global peptide drug/API/CDMO enterprise competitive analysis
1. Enterprise Tier System¶
Based on peptide business revenue, technical capability, pipeline depth, and globalization level, this report classifies global peptide enterprises into three tiers:
| Tier | Classification Criteria | Representative Companies | Count |
|---|---|---|---|
| Tier 1 | Peptide revenue > $10B, global operations, blockbuster innovative drugs | Novo Nordisk, Eli Lilly | 2 |
| Tier 2 | Peptide revenue $0.5-10B, regional leaders or CDMO giants | WuXi AppTec, Sinopeptide, Hybio, Pfizer, AstraZeneca | 15-20 |
| Tier 3 | Peptide revenue < $0.5B, focused on niche tracks or emerging companies | Shengnuo Biotechnology, Jiuzhou Pharma, Innovent, Hengrui, etc. | 50+ |
2. Tier 1: Global Giants¶
2.1 Novo Nordisk¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | $26.0B |
| Global Market Share | 57.5% |
| Core Products | Semaglutide (Ozempic + Wegovy + Rybelsus) |
| Core Product Sales | $212B (2024) |
| R&D Pipeline | Oral Amycretin (GIP/GLP-1 dual), Monlunabant (CB1 antagonist) |
Competitive Advantages: - First-mover advantage: Semaglutide was the first GLP-1 drug approved for obesity indication globally - Oral formulation leadership: Rybelsus is the only marketed oral GLP-1 drug - Production scale: In-house capacity + CDMO outsourcing, 2025 planned capacity increase to 120 tons/year - Brand moat: Extremely high Ozempic/Wegovy brand recognition
Strategic Shortcomings: - GLP-1 pipeline concentration risk - Patent expirations from 2026 (US patent litigation ongoing) - Oral formulation bioavailability (only 1%) limitations
2.2 Eli Lilly¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | $13.5B |
| Global Market Share | 29.9% |
| Core Products | Tirzepatide (Mounjaro + Zepbound), Dulaglutide (Trulicity) |
| Core Product Sales | $115B (Tirzepatide 2024) |
| R&D Pipeline | Retatrutide (triple target), Orforglipron (oral small molecule GLP-1) |
Competitive Advantages: - GIP/GLP-1 dual-target mechanism, weight loss efficacy superior to semaglutide - Oral small molecule GLP-1 (Orforglipron) pipeline leading (Phase III) - Massive capacity expansion: $9B investment in new capacity - Diversified pipeline: non-peptide oral GLP-1, triple-target drugs
Strategic Shortcomings: - Tirzepatide dose escalation causing supply constraints - Trulicity facing semaglutide competition, share declining - Oral tirzepatide (Phase III) less promising than Orforglipron
3. Tier 2: Regional Leaders and CDMO Giants¶
3.1 WuXi AppTec (WuXi TIDES)¶
| Metric | Data |
|---|---|
| 2024 Peptide CDMO Revenue | ¥5.8B (~$0.8B) |
| Global CDMO Market Share | ~25% |
| Core Capability | Integrated peptide CRDMO services |
| Capacity Scale | Solid-phase synthesis 40,000L (2024) |
Competitive Advantages: - World's largest peptide CDMO, covering full chain from R&D to commercialization - Rapid capacity expansion (2026 plan to expand to 60,000L) - Strong customer stickiness, contract backlog approximately $2B - Well-established FDA certification, leading internationalization capability
3.2 Sinopeptide¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | ¥2.8B (~$0.39B) |
| Core Business | GLP-1 API, peptide CDMO |
| Capacity Scale | Solid-phase synthesis 2,000 kg/year |
Competitive Advantages: - GLP-1 API (semaglutide, tirzepatide) cost advantage is significant - Long-term API supply contracts with overseas pharmaceutical companies - 2024 capacity utilization exceeded 95%
3.3 Hybio Pharmaceutical¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | ¥2.1B (~$0.29B) |
| Core Products | Liraglutide injection, peptide API |
| Internationalization | US FDA-certified API exports |
Competitive Advantages: - Leading domestic position in peptide generic drug injectables - Liraglutide generic approved in 2025, capturing GLP-1 generic first-mover advantage - Peptide injectable smart manufacturing plant, annual capacity 200 million units
3.4 Pfizer¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | ~$1.2B |
| Core Products | Various rare disease peptide drugs |
| Pipeline | GLP-1 related, antimicrobial peptides |
Characteristics: Entering the peptide field through M&A and partnerships; acquired Biohaven in 2023 for peptide drug platform, but relatively lagging in GLP-1 space.
3.5 AstraZeneca¶
| Metric | Data |
|---|---|
| 2024 Peptide Revenue | ~$0.9B |
| Core Products | Endocrine peptide drugs |
| Partnerships | Collaborating with multiple Chinese CDMOs on GLP-1 APIs |
4. Tier 3: Emerging Companies and Niche Track Players¶
4.1 Chinese Emerging Companies¶
| Company | Core Direction | Development Stage | Key Highlights |
|---|---|---|---|
| Innovent Biologics | GLP-1 innovative drug | NDA Review | Mazdutide (GCG/GLP-1) |
| Hengrui Medicine | GLP-1 innovative drug | Phase III | Noliglipin |
| Shengnuo Biotechnology | CDMO + Generics | Growing | GLP-1 API, peptide injectables |
| Jiuzhou Pharma | CDMO | Expanding | New peptide CDMO capacity |
| Asymchem | Peptide CDMO | Expanding | Continuous flow synthesis technology |
| Chengdu Shengnuo | Peptide generics | Stable | API exports |
4.2 Global Emerging Companies¶
| Company | Core Direction | Core Pipeline |
|---|---|---|
| Viking Therapeutics | GLP-1/GCG dual target | VK2735 (subcutaneous/oral) |
| Altimmune | GLP-1/GCG dual target | Pemvidutide |
| Zealand Pharma | Multiple glucagon peptides | Survodutide (GCG/GLP-1, partnering with BI) |
| Structure Therapeutics | Oral small molecule GLP-1 | GSBR-1290 (Phase II) |
5. M&A and Capital Trends¶
5.1 Recent Major M&A Events¶
| Date | Acquirer | Target | Deal Value | Strategic Intent |
|---|---|---|---|---|
| 2023 | Novo Nordisk | Embark Biotech | M&A | Acquire oral GLP-1 technology |
| 2024 | Eli Lilly | Versanis Bio | $1.9B | Acquire obesity new target bimagrumab |
| 2024 | WuXi AppTec | Peptide capacity expansion | $0.5B | Build new CDMO base |
| 2025 | Multiple Chinese pharma | Overseas API companies | Multiple deals | Expand global capacity |
5.2 Investment Hotspots¶
| Investment Direction | Heat | Representative Cases |
|---|---|---|
| Oral GLP-1 formulations | ★★★★★ | Multiple biotechs received large financing rounds |
| Multi-target agonists | ★★★★☆ | Retatrutide drawing significant attention |
| Peptide CDMO capacity expansion | ★★★★☆ | WuXi AppTec, Sinopeptide substantially expanding |
| Cosmetic peptide raw materials | ★★★☆☆ | Active domestic substitution investments |
| Peptide AI design platforms | ★★★☆☆ | Increasing investment in AI-assisted peptide screening |
6. Competitive Landscape Outlook (2025-2030)¶
6.1 Landscape Evolution Trends¶
- Tier 1 Duopoly Loosening: After GLP-1 generics enter in 2026, Novo Nordisk + Eli Lilly combined share will decline from 87% to 60-65%
- China CDMO Status Rising: WuXi AppTec is positioned to become a global peptide CDMO pricing power
- Innovation vs Generic Watershed: Companies with oral formulation and multi-target technology platforms will gain differentiated advantages
- Vertical Integration: Large pharma's trend toward building in-house peptide capacity accelerating; CDMOs evolving toward more focused technology platforms
6.2 2028 Predicted Landscape¶
| Type | 2030E Market Share | Representative Companies |
|---|---|---|
| Innovative Drug Giants | 60-65% | Novo Nordisk, Lilly, New Entrants |
| Generic Drug Companies | 15-20% | Indian/Chinese generic pharma |
| CDMO Service Providers | 10-15% | WuXi AppTec, Sinopeptide, Lonza, Bachem |
| Emerging Technology Platforms | 5-10% | Oral delivery, AI design companies |
Conclusion¶
The global peptide industry competitive landscape is undergoing a transformation from "dual monopoly" toward "multi-polar fragmentation." Tier 1 companies will maintain dominance through first-mover advantages and brand moats, but Tier 2 CDMO giants and Tier 3 innovative companies are accelerating their pursuit. For Chinese enterprises, CDMO capability advantages and API capacity advantages represent the most realistic competitive breakthrough points at the current stage.
Data Sources
Competitive landscape data is compiled from 2024 annual reports of respective companies, Yaozhi.com, Evaluate Pharma, industry interviews, and other publicly available information.
For more peptide enterprise competitive analysis → SENO Biotechnology Corporate Overview. SENO Biotechnology continuously tracks global peptide industry dynamics, providing professional market intelligence and CDMO services to industry clients.